WO2010031657A2 - Use of urea derivatives and phenacylthiazolium salts for the treatment of body odour - Google Patents

Abstract

The present invention relates to the use of urea derivatives and phenacylthiazolium salts for the inhibition of enzymes, in particular the cystathionine-beta-lyase, and/or for the prevention or treatment of body odour, in particular in the axillary or oral region, and to cosmetic and pharmaceutical preparations, in particular deodorants and antiperspirants containing said active substances.

Description

 Use of urea derivatives and phenacylthiazolium salts for the treatment of

body odor

The present invention relates to the use of urea derivatives and phenacylthiazolium salts for the inhibition of enzymes, in particular cystathionine beta-lyase, and / or for the prevention or treatment of body odor, in particular in the axillary or oral area, as well as cosmetic and pharmaceutical preparations, in particular deodorants and antiperspirants containing these active substances.

In the meantime, it has been proven that body odor primarily results from the breakdown of sweat constituents by bacteria of the skin flora, especially in the axillary area. In addition to perfumes to cover body odor so far mainly in deodorants to prevent body odor unselective effective biocides used to kill the bacteria in the axillary area. However, the use of unselective antibacterial substances has the disadvantage that even bacteria that cause no odor, are inhibited or killed. The protective function of the skin emanating from these bacteria is thus destroyed by the use of unselective antibacterial agents. In addition, it is known that many antibacterial agents have a bad effect against body odor. From this it can be concluded that the odor-producing bacteria are not or only insufficiently inhibited by the antibacterial agents used or that there may be connections in the bacterial community (eg hitherto unknown odor-producing species), their effects on the formation of body odor from the substances used be recorded.

A similar problem as for body odor is also for bad breath. Again, the starting substances are bacterially converted into malodorous degradation products. There is therefore still a need to have available agents for controlling body odor, in particular for the axillary and oral area, in particular those which are more effective against body odor and / or bad breath than the previously known agents, preferably without an unselective antibacterial Effect at the site of application. In this context, it is known that highly malodorous components of human body odor and halitosis are volatile sulfur compounds released by enzymatic reaction ("VSC") Sulfur-containing compounds, as water-soluble amino acid conjugates, sweat onto human skin they are released from skin bacteria (especially staphylococci and corynebacteria) by enzymatic reaction.

An enzyme that plays a key role in the release of VSCs is cystathionine beta-lyase. This enzyme breaks down VSCs from the amino acids and is thus an important cause of the development of body odor (see, for example, Natsch et al. (2004) Chemistry and Biodiversity 1, 1058-1072; Troccaz et al. (2004) Chemistry and Biodiversity 1, 1022-1035; Starkenmann et al. (2005) Chemistry and Biodiversity 2, 705-716).

In order to find active substances for the prevention of body odor, it is therefore proposed in WO 2006/079934 to search for substances which inhibit the formation of VSC starting from their precursors in the presence of cystathionine-beta-lyase. As such substances, in particular, molecules are mentioned in this document which are structurally similar to the precursors of the VSC, so that the mechanism of action of these substances presumably lies in a competitive blocking of the active center of cystathionine-beta-lyase. An advantage of the use of substances that specifically inhibit the enzyme activity of cystathionine beta-lyase, is that a more targeted control of the cause of the odor can occur and preferably continue to be largely dispensed with the use of antibacterial active substances, or at least limited their use can.

It was therefore a particular object of the present invention to search for further substances which specifically inhibit the activity of cystathionine-beta-lyase and thus could represent promising dioecolic active substances.

As an enzyme for the detection of inhibitory properties, for example, the cystathionine beta-lyase from Staphylococcus is. For example, benzyl cysteine can be used as a substrate for cystathionine beta-lyase. The enzymatic conversion of benzyl cysteine liberates cysteine, which can then be detected by detection reagents. For example, monobromobimane forms a fluorescent complex with cysteine, which can be detected spectrometrically. Inhibitors reduce the activity of cystathionine beta-lyase and thereby also the amount of detectable released cysteine.

Surprisingly, it has now been found that a very effective inhibition of cystathionine beta-lyase can be achieved by urea derivatives and phenacylthiazolium salts.

A first aspect of the present invention is therefore the use of urea derivatives, phenacylthiazolium salts or mixtures thereof for inhibiting an enzyme, which enzyme is preferably a cystathionine beta-lyase and which is preferably used in a cosmetic composition he follows.

The present invention therefore furthermore relates to the use of urea derivatives, phenacylthiazolium salts or mixtures thereof for the prevention or treatment of body odor, in particular in the axillary or oral area, the use preferably being carried out in a cosmetic agent.

The present invention furthermore relates to cosmetic or pharmaceutical compositions for the treatment or prevention of body odor or halitosis containing urea derivatives, phenacylthiazolium salts or mixtures thereof. The present invention therefore furthermore also relates to the use of urea derivatives, phenacylthiazolium salts or mixtures thereof for the preparation of a cosmetic or pharmaceutical composition for the treatment or prevention of body odor, in particular in the axillary or oral area.

The urea derivative to be used according to the invention is preferably a sulfonylurea, sulfonylthiourea, acylurea or acylthiourea. The sulfonylurea is a compound with the structural element

the acylurea is a compound with the structural element

the sulfonyl thiourea is a compound with the structural element

and the acylthiourea is a compound having the structural element

It is preferably in the sulfonylurea to a compound having the general formula R ¹ -SO ₂ -NX-C (O) -NY-R ² , wherein the acyl urea is a compound of the general formula R ¹ -C (O) -NX -C (O) -NY-R ² , in which sulfonylthiourea is a compound of the general formula R ¹ -SO ₂ -NX-C (S) -NY-R ² and in the case of the acylthiourea a compound of the general formula R ¹ - C (O) -NX-C (S) -NY-R ² , each being characterized in that X, Y, R ¹ and R ² independently of one another for trifluoromethyl, hydrogen, alkyl, in particular C |. ₂₂ alkyl, preferably C _1-18 alkyl, cycloalkyl, in particular C ₃ . ₈ -cycloalkyl, cycloalkylalkyl, in particular C ₃ . ₈ -cycloalkyl-C- |. ₁₂ alkyl, alkenyl, in particular C ₂ -i ₈ alkenyl, alkynyl, in particular C ₂ -i ₈ alkynyl, heteroalkyl, heterocycloalkyl, alkoxy, in particular Ci_i ₈ alkoxy, alkoxyalkyl, especially C ₁ - _I8 - alkoxy-Ci i ₈ alkyl, alkylsulfanyl, especially Ci_i ₈ alkylsulfanyl, alkylsulfinyl, especially C _1-18 - alkylsulphinyl, alkylsulphonyl, in particular Ci- ₁₈ alkylsulfonyl, alkanoyl, especially Ci_i ₈ alkanoyl, alkanoyloxy, in particular Ci_i ₈ alkanoyloxy, hydroxycarbonyl, alkoxycarbonyl, in particular C _{1- 18} alkoxycarbonyl, alkylaminocarbonyl, especially C-is-alkylaminocarbonyl, alkyl sulfanylcarbonyl, in particular Ci- ₁₈ -Alkylsulfanylcarbonyl, hydroxy, hydroxyalkyl, especially hydroxy-C |. ₁₈ alkyl, amino, alkylamino, in particular (. C- | ₁₈ alkyl) NH or di- (C _1-18 -AIRyI) N, aryl, especially C _6-10 aryl, arylalkyl, in particular C _6-10 - Aryl-C _1-12 -alkyl, aryloxy, in particular C _6-10 - aryloxy, arylamino, in particular C _6-1 o-arylamino, arylsulfanyl, in particular C _6-1 o-arylsulfanyl, arylsulfinyl, in particular C _6-1 o- Arylsulfinyl, arylsulfonyl, in particular C _6-1 o-arylsulfonyl, arylcarbonyl, in particular C _6-1 o-arylcarbonyl, arylcarbonyloxy, in particular C _6-10 arylcarbonyloxy, aryloxycarbonyl, in particular C _6-10 aryloxycarbonyl, arylaminocarbonyl, in particular

Arylsulfanylcarbonyl, in particular C _6-10 arylsulfanylcarbonyl, heteroaryl, heteroarylalkyl, in particular heteroarylC _1-12 -alkyl, heteroaryloxy, heteroarylamino, heteroarylsulfanyl, heteroarylsulfonyl, heteroarylsulfoxidyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heteroarylaminocarbonyl, heteroarylsulfanylcarbonyl, Alkoxysulfonyl, in particular C _1-18 alkoxysulfonyl, alkoxycarbinol, in particular C _1-12 alkoxycarbinol, sulfo, sulfino, sulfeno, formyl or thioformyl, all radicals of the resulting molecule, in particular the aliphatic and aromatic radicals each independently may also be mono- or polysubstituted, in particular mono-, di- or trisubstituted, preferably monosubstituted, substituted, in particular by substituents selected from the abovementioned radicals and selected from halogen, in particular chlorine, bromine, iodine or fluorine, and nitro.

In a particularly preferred embodiment, X is hydrogen and Y, R ¹ and R ² independently of one another are trifluoromethyl, alkyl, in particular C _1-22 -alkyl, preferably C _1-18 -alkyl, cycloalkyl, in particular C _3-8 -cycloalkyl, Cycloalkylalkyl, in particular C _3-8 -cycloalkyl-C _1-12 -alkyl, alkenyl, in particular C _2-18 -alkenyl, alkynyl, in particular C _2-18 -alkynyl, heteroalkyl, heterocycloalkyl, alkanoyl, in particular C _1-18 -alkanoyl , Hydroxycarbonyl, alkoxycarbonyl, in particular C _1-18 -alkoxycarbonyl, alkylaminocarbonyl, in particular C- _M s -alkylaminocarbonyl, alkylsulfanylcarbonyl, in particular C- _M s -alkylsulfanylcarbonyl, aryl, in particular C _6-10 -aryl, arylalkyl, in particular C _6-10 aryl-C _1-12 alkyl, arylcarbonyl, especially C _6-10 aryl-carbonyl, aryloxycarbonyl, especially C _6-10 aryloxycarbonyl, arylaminocarbonyl, in particular C _6-10 - arylaminocarbonyl, Arylsulfanylcarbonyl, in particular C _6-10 -Arylsulfanylcarbonyl, Heteroaryl, heteroarylalkyl, i in particular heteroaryl-C _1-12 -alkyl, heteroarylcarbonyl, heteroaryloxycarbonyl, heteroarylaminocarbonyl, heteroarylsulfanylcarbonyl or formyl, where preferably also Y is hydrogen, and where all the radicals of the resulting molecule, in particular the each aliphatic and aromatic radicals may each independently be optionally mono- or polysubstituted, in particular mono-, di- or trisubstituted, preferably monosubstituted, in particular by substituents selected from the abovementioned radicals and selected from halogen, in particular chlorine, bromine, iodine or fluorine, hydroxy, hydroxyalkyl, in particular hydroxy-C _1-8 -alkyl, hydroxycarbonyl, hydroxycarbonylalkyl, in particular hydroxycarbonyl-d- _18- alkyl, alkoxy, in particular C _1-8 -alkoxy, alkoxyalkyl, in particular C _1-18 -alkoxy-C 1-4 -alkyl. ₁₈ alkyl, alkoxycarbonyl, especially C- |. ₁₈ alkoxycarbonyl, alkoxycarbonylalkyl, especially C- |. ₁₈ -alkoxy-carbonyl-C |. ₁₈ alkyl, amino, alkylamino, particularly (C- |. ₁₈ alkyl) NH or di- (. C- | ₁₈ alkyl) N, alkanoyloxy, in particular C- |. ₁₈ alkanoyloxy, alkylsulfonyl, in particular C- |. ₁₈ alkylsulfonyl, arylsulfonyl, especially C _{6 10} arylsulfonyl, nitro or sulfo. In a further particularly preferred A In the embodiment, X and Y independently of one another are hydrogen or C - |. ₆ alkyl, preferably hydrogen, and R ¹ and R ^{2 are} independently alkyl, in particular C |. ₁₈ -alkyl, aryl, in particular phenyl, or arylalkyl, in particular phenyl-C- |. ₆ -alkyl, wherein said radicals may optionally also be mono- or polysubstituted, in particular by radicals selected from alkyl, in particular C |. ₁₈ -alkyl, halogen, in particular chlorine, bromine or fluorine, hydroxy, hydroxyalkyl, in particular hydroxy-C |. ₁₈ -alkyl, hydroxycarbonyl, hydroxycarbonylalkyl, especially hydroxycarbonyl-C |. ₁₈ -alkyl, alkoxy, in particular C |. ₁₈ -alkoxy, alkoxyalkyl, in particular C _1-18 -alkoxy-C- |. ₁₈ -alkyl, alkoxycarbonyl, in particular C |. ₁₈ alkoxycarbonyl, alkoxycarbonylalkyl, especially C _M s-alkoxy-carbonyl-Ci.-is-alkyl, amino, alkylamino, in particular (. C- | ₁₈ alkyl) NH or di- (C- |. ₁₈ alkyl) N, alkanoyloxy, especially C-ι_ ₁₈ alkanoyloxy, alkylsulfonyl, especially C- |. _18- alkylsulfonyl, arylsulfonyl, in particular C ₆ --ιo-arylsulfonyl, nitro or sulfo. In a further particularly preferred embodiment X and Y is hydrogen, R ¹ is an optionally substituted radical selected from alkyl, in particular C-ι_ ₁₈ alkyl, aryl, in particular phenyl, and aralkyl, especially phenyl-C |. ₆ -alkyl, and R ^{2 represents} by at least one hydroxy group, C-ι_ ₆ alkoxy group, hydroxy-C-ι_ ₆ alkyl group, C ₁ . _6- alkoxy-C ₁ . _6- alkyl group, hydroxycarbonyl group, hydroxycarbonyl-C-ι_ ₆ alkyl group, C-ι_ ₆ alkoxycarbonyl group or Cie-alkoxycarbonyl-Cie-alkyl group and optionally substituted by further radicals alkyl, in particular C _{1 -18-} alkyl, aryl, in particular phenyl, or arylalkyl, in particular phenyl-C- |. _6- alkyl, wherein the substituents or further radicals are preferably selected from C-. ₆ alkyl, in particular methyl, halogen, in particular chlorine, bromine or fluorine, and further hydroxy, C |. ₆ -alkoxy-, hydroxy-C- |. ₆ -alkyl, C-ι- _6- alkoxy-C-e-alkyl, hydroxycarbonyl, hydroxycarbonyl-C |. ₆ -alkyl, C- |. ₆ alkoxycarbonyl or Ci. _6- alkoxycarbonyl-Ci. ₆ -alkyl groups.

In a very particularly preferred embodiment, X and Y are hydrogen, R ^{1 is} optionally substituted phenyl and R ² is at least one hydroxy group, Ci _-6 - alkoxy group, hydroxy-Ci. ₆ alkyl group, Ci- ₆ alkoxy-Ci- ₆ alkyl group, hydroxycarbonyl group, hydroxy-carbonyl-Ci- ₆ alkyl group, CI_ ₆ alkoxycarbonyl group or CI_ ₆ alkoxycarbonyl Ci ₆ - Alkyl group and optionally substituted by further radicals substituted phenyl, wherein the Substituents or further substituents are preferably selected from C ₁ _ ₆ -AI ky I, in particular methyl, halogen, in particular chlorine, bromine or fluorine, and further hydroxy, C ₁ . ₆ -alkoxy-, hydroxy-C- |. ₆ -alkyl-, C- |. ₆ -alkoxy-C- |. _6- alkyl, hydroxycarbonyl, hydroxycarbonyl-C-ι_ ₆ - alkyl, Ci_ ₆ alkoxycarbonyl or de-alkoxycarbonyl-Cie-alkyl groups.

In this very particularly preferred embodiment, the urea derivative is a sulfonylurea according to formula (I) or (II)

or a sulfonylthiourea according to formula (IM) or (IV)

or mixtures thereof, each with R = hydrogen or C- |. _6- alkyl and wherein the alkyl and aryl groups of the abovementioned compounds of the formulas (I), (II), (III) and (IV) are each, if desired, further substituents, in particular those selected from those mentioned above, in particular those selected from ₆ alkyl, in particular methyl, halogen, in particular chlorine, bromine or fluorine, and further hydroxy, Ci_ ₆ alkoxy, hydroxy Ci_ ₆ alkyl, Ci. _6- alkoxy-Ci. ₆ -alkyl, hydroxycarbonyl, hydroxycarbonyl-d- _6- alkyl, Ci_ ₆ alkoxycarbonyl or Cie-alkoxycarbonyl-Cie-alkyl groups can carry.

The phenacylthiazolium salt which can be used according to the invention preferably comprises a cation of the formula (V)

said compound also mono- or polysubstituted, preferably mono-, di- or trisubstituted may be substituted, preferably by previously mentioned with respect to the urea derivatives substituents, in particular by substituents selected from CI_ ₆ alkyl, in particular methyl, halogen, in particular chloro, bromo or fluoro, hydroxy, CI_ ₆ alkoxy, hydroxy-C-ι- ₆ alkyl, Ci. _6- alkoxy-Ci. _6- alkyl, hydroxycarbonyl, hydroxycarbonyl-Ci_ ₆ alkyl, Ci _-6 - alkoxycarbonyl and de-Altoxycarbonyl-de-alkyl.

The counterion of the phenacylthiazolium cation may be any counterion. In a preferred embodiment, the counterion is selected from halogen anions. Most preferably, the compound is phenacylthiazolium chloride. Ci_i ₈ alkyl according to the invention in each case independently of one another for all saturated linear and branched alkyl radicals having up to 18 carbon atoms, with Ci_ ₆ alkyl radicals are preferred. Ci_ ₆ alkyl according to the invention for all saturated linear and branched alkyl radicals having up to 6 carbon atoms, in particular methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl and all Isomers of pentyl and hexyl.

C ₃ . According to the invention, ₈ -cycloalkyl in each case independently of one another represents all cyclic alkyl radicals having 3 to 8 C atoms, preferably having 5 to 6 C atoms, where the radicals may be saturated or unsaturated, in particular cyclopentyl, cyclohexyl or cyclopentadienyl.

C ₂ -i ₈ -alkenyl according to the invention in each case independently of one another for all linear and branched alkyl radicals having up to 18 carbon atoms, containing at least one double bond, C ₂ - ₆ alkenyl radicals are preferred. C ₂ - ₆ alkenyl according to the invention represents all linear and branched alkyl radicals having up to 6 C atoms which contain at least one double bond, in particular ethenyl, propenyl, i-propenyl and all isomers of butenyl, pentenyl and hexenyl.

C ₂ _i ₈ -Alkinyl according to the invention in each case independently of one another for all linear and unbranched alkyl radicals having up to 18 carbon atoms, which contain at least one triple bond, wherein C ₂ . ₆ alkynyl radicals are preferred. C ₂ . ₆ -alkynyl according to the invention represents all linear and unbranched alkyl radicals having up to 6 C atoms which contain at least one triple bond, in particular ethynyl, propynyl, i-propynyl and all isomers of butynyl, pentynyl and hexynyl.

Heteroalkyl according to the invention in each case independently of one another for all saturated and mono- or polyunsaturated, linear or branched alkyl radicals containing at least one, preferably exactly one heteroatom, in particular selected from O, S and N, wherein the sum of C and Heteroatoms preferably up to 18, more preferably up to 6, is. Heterocycloalkyl according to the invention is in each case independently of one another for all cyclic alkyl radicals which contain at least one, preferably exactly one, heteroatom, in particular selected from O, S or N, wherein the ring is preferably from three to eight membered, more preferably five to six membered , Examples of these are tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, 2- Thiazolinyl, tetrahydrothiazolyl, tetrahydrooxazolyl, piperidinyl, piperazinyl, morpholinyl and

Thiomorpholinyl.

. C | According to the invention, ₁₈ -alkoxy in each case independently of one another represents all saturated and unsaturated, linear and branched alkyl radicals having up to 18 C atoms which have a

Oxygen atom are bonded, wherein Ci_ ₆ alkoxy radicals are preferred. CI_ ₆ alkoxy in the present invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms, which are bonded via an oxygen atom, in particular methoxy and ethoxy.

C-ι- ₁₈ alkylsulfanyl is according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals with up to 18 C atoms, which an

Sulfur atom are bonded, with C-ι_ ₆ alkylsulfanyl radicals are preferred. _C-6 alkylsulfanyl ι_ is according to the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms bonded via a sulfur atom, in particular for Methysulfanyl and ethylsulfanyl.

C "i- alkylsulfinyl ₁₈ is according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms, which has a SO-

Group are bound, where C- |. _6- Alkylsulfonyl radicals are preferred. . C | According to the invention, _6- alkylsulfinyl stands for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 C atoms which are bonded via an SO group, in particular for methylsulfinyl and

Ethylsulfinyl.

C-ι- ₁₈ -alkylsulphonyl according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms, which has a SO ₂ -

Group are attached, wherein Ci_ ₆ alkylsulfoxidyl radicals are preferred. CI_ ₆ alkylsulfonyl is according to the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 C-atoms which ₂ group are bonded via a SO, in particular methylsulfonyl and

Ethylsulfonyl.

C "i- ₁₈ alkanoyl is according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms, which are bonded via a carbonyl group, said C- |. ₆ alkanoyl . residues are preferred C- |. ₆ alkanoyl according to the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms, which are bonded via a carbonyl group, in particular Methycarbonyl and ethylcarbonyl.

. C | ₁₈ alkanoyloxy according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms which are bonded via a carbonyloxy group, CI_ ₆ alkanoyloxy radicals are preferred. Ci _-6 - alkanoyloxy according to the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms, which are bonded via a carbonyloxy group, in particular methanoyloxy, ethanoyloxy, n-propanoyloxy and i-propanoyloxy. C- |.-I ₈ -alkoxycarbonyl according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms which are bonded through an oxycarbonyl group, said C- |. ₆ alkoxycarbonyl radicals are preferred. Ci _-6 - alkoxycarbonyl accordance with the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms, which are bonded via an oxycarbonyl group, in particular methoxycarbonyl and ethoxycarbonyl.

Ci- ₁₈ alkylaminocarbonyl stands according to the invention each independently represents an aminocarbonyl group is substituted one or two times by a saturated or unsaturated, linear or branched alkyl radical having up to 18 C atoms, where one or two times by CI_ _6- Alkyl groups substituted aminocarbonyl radicals, in particular monomethylaminocarbonyl, diemethylaminocarbonyl, monoethylaminocarbonyl and diethylaminocarbonyl, are preferred. Ci- ₁₈ -Alkylsulfanylcarbonyl is according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms, which are bonded via a thiocarbonyl group, CI_ ₆ -Alkylsulfanylcarbonyl radicals are preferred. Ci- ₆ -Alkylsulfanylcarbonyl is according to the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms, which are bonded via a thiocarbonyl group, in particular methylthiocarbonyl and ethylthiocarbonyl.

(Ci_i ₈ alkyl) NH is according to the invention each independently of one another for all saturated and unsaturated, linear and branched alkyl radicals having up to 18 carbon atoms, which are bonded via a hydrogenamino group, (Ci. ₆ alkyl) NH is preferred , (Ci. ₆ alkyl) NH according to the invention for all saturated and unsaturated, linear and branched alkyl radicals having up to 6 carbon atoms, which are bonded via a Hydrogenamino-group, in particular CH ₃ NH and C ₂ H ₅ NH ,

Di (C-i ₈ alkyl) N stands according to the invention are each independently, all saturated and unsaturated, linear and branched alkyl groups having up to 18 carbon atoms, which has a (C _1-18 - alkyl) amino group are bonded wherein di- (Ci_ ₆ alkyl) N is preferred. The two alkyl radicals here may be the same or different from each other. Di- (CI_ ₆ alkyl) N stands according to the invention for all saturated and unsaturated, linear and branched alkyl groups having up to 6 carbon atoms, which are bonded via a (CI_ ₆ alkyl) amino group, in particular (CH _{3) 2} N and (C ₂ Hs) ₂ N.

C ₆ -io-aryl according to the invention, in particular also in C ₆ -io-aryl-Ci_i ₂ -alkyl, C ₆ -io-aryloxy, C ₆ -o-arylamino, C ₆ -io-arylsulfanyl, C ₆ -io- arylsulfonyl, C ₆ -io-Arylsulfoxidyl, C ₆ -io arylcarbonyl, C _6- io arylcarbonyloxy, C ₆ -io aryloxycarbonyl, C ₆ -io-arylaminocarbonyl and C ₆ -io-Arylsulfanylcarbonyl, preferably phenyl or naphthyl, especially preferred for phenyl.

Heteroaryl is according to the invention, in particular in heteroaryl-Ci_i _2- alkyl, heteroaryloxy, heteroarylamino, heteroarylsulfanyl, heteroarylsulfonyl, heteroarylsulfoxidyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heteroarylaminocarbonyl and

Heteroarylsulfanylcarbonyl, unless stated otherwise, for an aromatic radical having from 5 to 10, preferably 5 or 6, at least one heteroatom selected from O, S and N, Ring members, preferably selected from furanyl, thienyl, thiophenyl, pyrrolyl, isopyrrolyl,

Pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,

Triazinyl, benzofuranyl, benzothiophenyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl,

Indazolyl, pyridofuranyl and pyridothienyl.

In C ₆ -io-aryl-Ci-i ₂ -alkyl and heteroarylalkyl, the alkyl radical may be saturated or unsaturated, branched or unbranched. Preferred radicals are benzyl, phenylethyl, naphthylmethyl and

Naphthylethyl.

Urea derivatives and / or phenacylthiazolium salts to be used according to the invention are preferably present in the compositions according to the invention in an amount of up to 20% by weight, more preferably in amounts of from 0.001 to 10% by weight, in particular from 0.01 to 5% by weight .-%, especially of

0.1-2% by weight.

The cosmetic or pharmaceutical composition according to the invention may be any dosage form, for example a solid or liquid

Soap, a lotion, a spray, a cream, a gel, an emulsion, a cleansing liquid or

Cleansing milk, a stick, a deodorant, an antiperspirant or an ointment and it may also be contained in any of the described or other dosage forms, for example, in a patch, especially in a gel reservoir or matrix patch.

In a particularly preferred embodiment according to the invention, the cosmetic or pharmaceutical composition is a deodorant and / or

Antiperspirant. The deodorant and / or antiperspirant here is preferably in the form of powder, in

Pen shape, as syndet, wash lotion, aerosol spray, pump spray, liquid or gel roll on

Application, cream, foam, liquid or solid soap, gel or impregnated as a flexible substrate.

Depending on the type of application, the applicators may be, for example, pin barrel, roll-on,

Pump, tube, jar, dispenser, cloth, aerosol can or bottle can be used.

The site of application is the skin of each area of the body, in particular the facial skin, the scalp, the skin on the feet and hands. In a particularly preferred

Embodiment, the application site is the skin in the axillary area. In a further particularly preferred embodiment, the site of application is the oral area.

The cosmetic or pharmaceutical composition according to the invention may also contain other

Contain ingredients as the aforementioned. In a preferred embodiment, it contains at least one of the substances enumerated below. It can also be any one

Combination containing the ingredients listed below.

Cosmetic or pharmaceutical compositions which have been found to be particularly advantageous according to the invention are those which comprise mixtures of at least one urea derivative and / or phenacylthiazolium salt and at least one substance which is prebiotically active in the axillary region (as disclosed in WO2005 / 011716 or WO2005 / 092279), especially selected from plant extracts of Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp., Ribes sp., Camellia spec., Hibiscus sp., Malva sp., Vitis sp., Daucus sp., Commiphora sp., Simmondsia spec. or calendula spec, glycerol monoalkyl ethers, in particular α-monoalkyl glycerol ethers having a branched or linear saturated or unsaturated, optionally hydroxylated C ₆ -C ₂₂ -alkyl radical, particularly preferably 1- (2-ethylhexyl) glycerol ether, isopropyl myristate or ethyl myristate or mixtures thereof. The combination of on the one hand inhibitors of cystathionine beta-lyase and on the other hand in the axillary prebiotic active substances, on the one hand by the blocking of cystathionine beta-lyase, the formation of odor and simultaneously targeted the relationship between odor-forming and odorless bacteria in favor of odorless bacteria shifted so that a highly effective fight against body odor can be achieved.

Furthermore, cosmetic or pharmaceutical compositions which comprise mixtures of at least one urea derivative and / or phenacylthiazolium salt and at least one further deodorant active ingredient, in particular an antimicrobially active substance, preferably an aromatic alcohol, and in a preferred one have proved particularly advantageous according to the invention Embodiment additionally contain at least one of the aforementioned in the axillary area prebiotically active substances. The combined use of inhibitors of cystathionine beta-lyase and antimicrobial deodorant agents both reduce the number of odor-causing bacteria and reduce their odor-causing capacity. Due to the additional presence of a prebiotically active substance, the ratio between odor-causing bacteria and odor-neutral bacteria is further shifted in favor of the odor-neutral bacteria, so that an even more effective body odor control is possible as a result. Due to the combined effect of antimicrobial substances on the one hand and prebiotically active substances on the other hand, the desired bacteria are then more able to spread on the skin than would be the case in the presence of a purely prebiotic effect. The remaining undesirable, because odor causing, bacteria are effectively prevented by the inhibitors of cystathionine beta-lyase in the formation of odors.

Fragrances, odor absorbers, deodorizing ion exchangers, antimicrobial or germ-inhibiting substances, further enzyme-inhibiting substances, antioxidants and odor adsorbents are particularly suitable according to the invention as further deodorant active substances. Particularly suitable as odor absorbers are silicates. These also simultaneously support the rheological properties of the composition according to the invention in an advantageous manner. The silicates used particularly preferably according to the invention as odor absorbers include, in particular, layered silicates and, among these, in particular montmorillonite, kaolinite, mit, beidellite, nontronite, saponite, hectorite, bentonite, smectite and talcum. Further preferred odor absorbers are For example, zeolites, Zinkricinoleat, cyclodextrins, certain metal oxides, such as. As alumina, and chlorophyll.

Preferred antimicrobial or antimicrobial agents according to the invention are in particular organohalogen compounds and halides, quaternary ammonium compounds, a number of plant extracts and zinc compounds. Preference is given to triclosan (Irgasan® DP300), triethyl citrate, chlorhexidine, chlorhexidine gluconate, 3,4,4'-trichlorocarbanilide, bromochlorophene, dichlorophene, chlorothymol, chloroxylenol, hexachlorophene, dichloro-m-xylenol, dequalinium chloride, domiphenbromide, ammonium phenolsulfonate, and benzalkonium halides , Benzalkonium cetyl phosphate, benzalkonium saccharinates, benzethonium chloride,

Cetylpyridinium chloride, laurylpyridinium chloride, laurylisoquinolinium bromide and methylbenzethonium chloride. Furthermore, phenol, disodium dihydroxyethylsulfosuccinyl undecylenate, sodium bicarbonate, zinc lactate, sodium phenolsulfonate, zinc phenolsulfonate, ketoglutaric acid, bisabolol, terpene alcohols such as. As farnesol, chlorophyllin copper complexes, carboxylic acid esters of mono-, di- and triglycerol (eg., Glycerinmonolaurat, diglycerol monocaprate), lantibiotics and certain plant extracts (eg., Green tea and the components of lime blossom oil and chamomile oil) can be used ,

Preferred further enzyme-inhibiting substances are inhibitors for further enzymes of the axillary germ flora, which are involved in the development of body odor. These are preferably inhibitors of lipases, arylsulfatases (see WO 01/99376), β-glucuronidases (see WO 03/039505), 5-α-reductases and aminoacylases.

Other antibacterial deodorant active ingredients are glycoglycerolipids, sphingolipids (ceramides), sterols and other agents that inhibit bacterial adhesion to the skin, e.g. As glycosidases, lipases, proteases, carbohydrates, di- and Oligosaccharidfettsäureester and alkylated mono- and oligosaccharides.

Also suitable as a deodorant active ingredient are water-soluble polyols selected from water-soluble diols, triols and higher-grade alcohols and also polyethylene glycols. Among the diols are C ₂ -C ₁₂ -DbIe, in particular 1, 2-propylene glycol, butylene glycols such as. B. 1, 2-Butylene glycol, 1, 3-Butylene glycol and 1, 4-Butylene glycol, pentanediols, z. B. 1, 2-pentanediol, and hexanediols, for. B. 1, 6-hexanediol. Also preferred are glycerol and technical Oligoglyceringemische with an intrinsic degree of condensation of 1, 5 to 10 such as technical Diglyceringemische having a Diglycerine content of 40 to 50 wt .-% or triglycerol, further 1, 2,6-hexanetriol and polyethylene glycols (PEG) with a average molecular weight of 100 to 1000 daltons, for example PEG-400, PEG-600 or PEG-1000. Other suitable higher alcohols are the C ₄ , C ₅ and C ₆ monosaccharides and the corresponding sugar alcohols, eg. Mannitol or sorbitol.

In a preferred embodiment, an aromatic alcohol is used as further deodorant active ingredient. The aromatic alcohol according to the invention is preferably a compound of the general formula

, in which

R ¹ - R ⁶ = independently of one another represent a hydrogen atom, a linear or branched and optionally substituted Ci_i _O alkyl group or a linear or branched and optionally substituted C ₂ -io-alkenyl, wherein the substituents are each preferably selected from hydroxy and C -ι_ ₆ alkoxy,

R ⁷ - R ¹¹ = independently represent a hydrogen atom, a halogen atom, in particular chlorine, or a linear or branched and optionally substituted C- _M o-alkyl group, wherein the substituents are preferably selected from hydroxy and C-. ₆ -alkoxy, especially methoxy, m = 0 or 1, n, o, p = can independently be integers from 0 to 10, wherein at least one of the values of n, o, p ≠ 0.

Aromatic alcohols of the aforementioned structure which are preferred according to the invention are selected from phenoxyethanol, phenoxyisopropanol (3-phenoxy-propan-2-ol), anisalcohol, 2-methyl-5-phenyl-pentan-1-ol, 1,1-dimethyl-3 phenyl-propan-1-ol, benzyl alcohol, 2-phenylethan-1-ol, 3-phenylpropan-1-ol, 4-phenylbutan-1-ol, 5-phenylpentan-1-ol, 2-benzylheptan-1-ol, 2,2-Dimethyl-3-phenylpropan-1-ol, 2,2-dimethyl-3- (3'-methylphenyl) -propan-1-ol, 2-ethyl-3-phenylpropan-1-ol, 2-ethyl -3- (3'-methylphenyl) -propan-1-ol, 3- (3'-chlorophenyl) -2-ethyl-propan-1-ol, 3- (2'-chlorophenyl) -2-ethyl-propan-1-ol, 3- (4'-Chlorophenyl) -2-ethyl-propan-1-ol, 3- (3 ', 4'-dichlorophenyl) -2-ethyl-propan-1-ol, 2-ethyl-3- (2'-methyl-phenyl) - propan-1-ol, 2-ethyl-3- (4'-methylphenyl) -propan-1-ol, 3- (3 ', 4'-dimethylphenyl) -2-ethyl-propan-1-ol, 2-ethyl -3- (4'-methoxyphenyl) -propan-1-ol, 3- (3 ', 4'-dimethoxyphenyl) -2-ethyl-propan-1-ol, 2-allyl-3-phenyl-propan-1-ol and 2- n-pentyl-3-phenyl-propan-1-ol. Antioxidant substances can counteract the oxidative decomposition of the welding components and in this way inhibit odor development. Preferred antioxidants are imidazole and imidazole derivatives (eg urocaninic acid), peptides, such as e.g. B. D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg, anserine), carotenoids, carotenes (eg, α-carotene, β-carotene, lycopene) and their derivatives, Lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thio compounds (eg thioglycerol, thiosorbitol, thioglycollic acid, thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl) , Ethyl, propyl, amyl, butyl, lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides , Lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (eg buthionine sulfoximines, homocysteine sulfoximine, buthionine sulfones, penta, hexa, Heptathionine sulfoximine) in very low tolerated dosages (eg pmol / kg to μmol / kg), furthermore metal chelators (eg α-hydroxy fatty acids, EDTA, EGTA, lactoferrin), humic acids, bile acid, bile extracts, catechins, bilirubin, biliverdin and their derivatives, unsaturated fatty acids and their derivatives (for example γ-linolenic acid, linoleic acid, arachidonic acid, oleic acid), folic acid and derivatives thereof, hydroquinone and its derivatives (for example arbutin), ubiquinone and ubiquinol and derivatives thereof, vitamin C and its derivatives (eg ascorbyl palmitate, stearate, dipalmitate, acetate, Mg ascorbyl phosphates, sodium and magnesium ascorbate, disodium ascorbyl phosphate and sulfate, potassium ascorbyl tocopheryl phosphate, chitosan ascorbate), isoascorbic acid and its derivatives, tocopherols and their derivatives (eg tocopheryl acetate, linoleate, oleate and succinate, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50, tocopherolan), vitamin A and derivatives (e.g. Vitamin A palmitate), the benzylic resin coniferyl benzoate, rutin, rutinic acid and derivatives thereof, disodium rubinyldisulfate, cinnamic acid and its derivatives, kojic acid, chitosan glycolate and salicylate, butylhydroxytoluene, butylated hydroxyanisole, nordihydroguaiacetic acid, nordihydroguiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof , Mannose and its derivatives, selenium and selenium derivatives (e.g. Selenium methionine), stilbenes and stilbene derivatives (eg, stilbene oxide, trans-stilbene oxide). Suitable derivatives (salts, esters, sugars, nucleotides, nucleosides, peptides and lipids) and mixtures of these active substances or anhydrous plant extracts containing these antioxidants can be used according to the invention.

Preferred lipophilic, oil-soluble antioxidants from this group are tocopherol and its derivatives, in particular tocopheryl acetate, and carotenoids, as well as butylhydroxytoluene and butylhydroxyanisole.

A preferred composition according to the invention contains at least one of the aforementioned additional deodorant active ingredients, wherein the total amount of additional deodorant active ingredients is preferably 0.1-10% by weight, preferably 0.2-7% by weight, particularly preferably 0.3 - 5 wt .-% and in particular 0.4 - 1, 0 wt .-% is.

Furthermore, cosmetic or pharmaceutical compositions which have been found to be particularly advantageous according to the invention have been found to comprise mixtures of at least one urea derivative and / or phenacylthiazolium salt and at least one antiperspirant active ingredient (antiperspirant active ingredient), preferably furthermore in combination with at least one prebiotic active substance and / or or another deodorant active ingredient. Suitable antiperspirant active substances according to the invention are, in particular, water-soluble astringent or protein coagulating metallic salts, in particular inorganic and organic salts of aluminum, zirconium, zinc and titanium, and any desired mixtures of these salts. According to the invention preferred antiperspirant active substances are selected from aluminum chlorohydrates, especially aluminum chlorohydrates having the general formula [Al ₂ (OH) ₅ CI 2-3 ^■ H ₂ O] _n, which may be present in non-activated or activated in (depolymerized) Form , furthermore aluminum sesquichlorohydrate, aluminum chlorohydrex-propylene glycol (PG) or polyethyleneglycol (PEG), aluminum sesquichlorohydrex-PG or -PEG, aluminum-PG-dichlorhydrex or Aluminum-PEG-dichlorohydrex, aluminum hydroxide, further selected from the aluminum zirconium chlorohydrates, such as aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium octachlorohydrate, the aluminum-zirconium-chlorohydrate-glycine complexes such as aluminum zirconium trichlorohydrex glycine,

Aluminum zirconium tetrachlorohydrexglycine, aluminum zirconium pentachlorohydrexglycine, aluminum zirconium octachlorohydrex glycine, potassium aluminum sulfate (KAl (SO ₄ ) ₂ ^.12H ₂ O, alum), aluminum undecylenoyl collagen amino acid, sodium aluminum lactate + aluminum sulphate, sodium aluminum chlorhydroxactate, aluminum bromohydrate, aluminum chloride, the complexes of zinc and sodium salts, the complexes of lanthanum and Cerium, the aluminum salts of lipoamino acids, aluminum sulfate, aluminum lactate, aluminum chlorohydrate, sodium aluminum chlorohydroxactate, zinc chloride, zinc sulfocarbolate, zinc sulfate and zirconium chlorohydrate. A solubility of at least 5 wt .-% at 20 ⁰ C is understood according to the invention, solubility in water, that is, amounts of at least 5 g of the antiperspirant active ingredient in 95 g of water are soluble at 20 ⁰ C. The antiperspirant active ingredients can be used as aqueous solutions.

In a particularly preferred embodiment, the inventive composition as antiperspirant comprises an astringent aluminum salt, especially aluminum chlorohydrate, for example, in powder form as Micro Dry ^® Ultrafine or Micro Dry ^® SUF from Reheis, in the form of an aqueous solution as Locron ^® L from Clariant, as Chlorhydrol ^® and in activated form as ^Reach® 103 or ^Reach® 501 from Reheis. Under the name ^Reach® 301 an aluminum sesquichlorohydrate from Reheis is offered, which is likewise particularly preferred. The use of aluminum zirconium Tetrachlorohydrex- glycine complexes, which are, for example, by Reheis under the name Rezal ^® 36G or Reach ^® 908 commercially, may be particularly preferred according to the invention. The antiperspirant active ingredient is contained in the compositions according to the invention in an amount of 0.01-40% by weight, preferably 2-30% by weight and more preferably 5-25% by weight. A composition according to the invention may also contain further and / or other plant extracts in addition to the abovementioned prebiotic active plant extracts. Plant extracts which can be used according to the invention can be prepared, for example, by extraction of the entire plant, but also exclusively by extraction from flowers and / or leaves and / or seeds and / or other parts of plants. According to the invention, especially the extracts from the meristem, so the divisible educated tissue of the plants, and the extracts of special plants such as green tea, witch hazel, chamomile, pansy, Paeonie, aloe vera, horse chestnut, sage, willow bark, cinnamon tree (cinnamon tree), Chrysanthemums, Oak bark, Stinging nettle, Hops, Burdock root, Horsetail, Hawthorn, Lime blossom, Almonds, Spruce needles, Sandalwood, Juniper, Coconut, Kiwi, Guava, Lime, Mango, Apricot, Wheat, Melon, Orange, Grapefruit, Avocado, Rosemary, Birch, Beech shoots, Meadowfoam, Yarrow, Quendel, Thyme, Melissa, Hauhechel, Marshmallow (Althaea), Violets, leaves of black currant, coltsfoot, Fünffingerkraut, ginseng, ginger root and sweet potato are preferred as another plant extract. Algae extra kte can also be used to advantage. The algae extracts used according to the invention are derived from green algae, brown algae, red algae or blue-green algae (cyanobacteria). The algae used for extraction can be obtained both from natural sources as well as by biotechnological processes and, if desired, be modified from the natural form. The alteration of the organisms may be by genetic engineering, by breeding or by cultivation in media enriched with selected nutrients. Preferred algae extracts are from seaweed, blue-green algae, from the green alga Codium tomentosum and from the brown algae Fucus vesiculosus. A particularly preferred algae extract is derived from blue-green algae of the species Spirulina, which were cultured in a magnesium-enriched medium.

The cosmetic or pharmaceutical compositions, and in particular the inventively preferred deodorant or antiperspirant compositions, may further contain fatty substances. Fatty substances are to be understood as meaning fatty acids, fatty alcohols, natural and synthetic cosmetic oil components as well as natural and synthetic waxes, which can be in solid or liquid form in aqueous or oily dispersion.

As fatty acids it is possible to use linear and / or branched, saturated and / or unsaturated C ₈ . _30- fatty acids. ₂₂ fatty acids - ₁₀ C are preferred. Examples are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidonic acid, gadoleic acid, behenic acid and erucic acid and their technical properties mixtures. Particularly preferred is the use of stearic acid. The fatty acids used can carry one or more hydroxyl groups. Preferred examples of these are the α-hydroxy-Cs-C-is carboxylic acids and 12-hydroxystearic acid. The amount used is 0.1 to 15 wt .-%, preferably 0.5 to 10 wt .-%, particularly preferably 1 to 5 wt .-%, each based on the total composition. As fatty alcohols it is possible to use saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 6 to 30, preferably 10 to 22 and very particularly preferably 12 to 22 carbon atoms. Decanols, octanols, dodecadienol, decadienol, oleyl alcohol, eruca alcohol, ricinoleic alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl are, for example, decanol, octanolol, dodecadienol, decadienol - kohol, as well as their Guerbet alcohols.

For pen formulations waxes are often used. As natural or synthetic waxes can be used according to the invention are solid paraffins or isoparaffins, plant waxes such as candelilla wax, carnauba wax, Espartograswachs, Japanwachs, cork wax, sugarcane wax, ouricury wax, Kesterwachs, montan wax, sunflower wax, fruit waxes and animal waxes such. B. beeswax and other insect waxes, spermaceti, Shellac wax, wool wax and raffia fat, continue to mineral waxes such. Ceresin and Ozokerit or the petrochemical waxes such. As petrolatum, paraffin waxes, Microwachse of polyethylene or polypropylene and polyethylene glycol waxes. It may be advantageous to use hydrogenated or hardened waxes. Furthermore, chemically modified waxes, especially the hard waxes, z. As montan ester waxes, Sasol waxes and hydrogenated jojoba waxes, can be used.

Also suitable are the mono-, di- and triglycerides of saturated and optionally hydroxylated Ci ₆ - ₃ o-fatty acids, such as. B. hydrogenated triglyceride fats (hydrogenated palm oil, hydrogenated coconut oil, hydrogenated castor oil (Cutina ^® HR)), glyceryl monostearate (Cutina ^® MD), glyceryl tribehenate or glyceryl tri-12-hydroxystearate, further synthetic Vollester of fatty acids and glycols (eg. B. Syncrowachs ^®) or polyols having 2 - 6 carbon atoms, fatty acid monoalkanolamides with one C ₁₂ - ₂₂ - acyl group and a C _2-4 alkanol, esters from saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 1 to 80 C- Atoms and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 1 to 80 carbon atoms, including z. Example, synthetic fatty acid fatty alcohol esters such as stearyl stearate or cetyl palmitate, esters of aromatic carboxylic acids, dicarboxylic acids or hydroxycarboxylic acids (eg., 12-hydroxystearic acid) and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 1 to 80 C-atoms, lactides of long-chain hydroxycarboxylic acids and full esters of fatty alcohols and di- and tricarboxylic acids, eg. As dicetyl succinate or dicetyl / stearyl adipate, and mixtures of these substances, provided that the individual wax components or their mixture are solid at room temperature.

The wax components are present in an amount of from 0.1 to 40% by weight, based on the total composition, preferably from 1 to 30% by weight and in particular from 5 to 25% by weight.

The compositions of the invention may further contain at least one nonpolar or polar liquid oil, which may be natural or synthetic. The polar oil component may be selected from vegetable oils, e.g. B. sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil and the liquid portions of coconut oil and synthetic triglyceride oils, from ester oils, that is, the esters of C ₆ - ₃ o-fatty acids with C ₂ - ₃ o-fatty alcohols, from dicarboxylic esters such Di-n-butyl adipate, di (2-ethylhexyl) adipate and di- (2-ethylhexyl) succinate and diol esters such as ethylene glycol dioleate and propylene glycol di (2-ethylhexanoate), from symmetrical, unsymmetrical or cyclic esters of carbonic acid with fatty alcohols, for example described in DE-OS 197 56 454, glycerol carbonate or dicaprylyl carbonate (Cetiol ^® CC), from mono, - di- and trifatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerol, branched alkanols, eg. B. Guerbet alcohols with a single branch on the carbon atom 2 such as 2-hexyldecanol, 2-octyldodecanol, isotridecanol and isohexadecanol, from alkanediols, eg. B. from Epoxyalkanen with 12 - 24 carbon atoms by ring opening with water available vicinal diols, from ether alcohols, eg. B. the monoalkyl ethers of glycerol, ethylene glycol, 1, 2 Propylene glycols or 1, 2-butanediol, from dialkyl ethers having in each case 12 to 24 carbon atoms, for. Example, the alkyl methyl ethers or di-n-alkyl ethers, each having a total of 12 to 24 carbon atoms, in particular di-n-octyl ether (Cetiol ^® OE ex Cognis), as well as adducts of ethylene oxide and / or propylene oxide to mono- or polyvalent C ₃ . ₂ o-alkanols such as butanol and glycerol, z. PPG-3-myristyl ether (Witconol APM ^®), PPG-14 butyl ether (Ucon Fluid ^® AP) PPG-15 stearyl ether (Arlamol ^® E), PPG-9-butyl ether (Breox B25 ^®) and PPG-10 butanediol (Macol ^® 57). The non-polar oil component may be selected from liquid paraffin oils, isoparaffin oils, e.g. Isohexadecane and isoeicosane, from hydrogenated polyalkenes, especially poly-1-decenes (commercially available as Nexbase 2004, 2006 or 2008 FG (Fortum, Belgium)), from synthetic hydrocarbons, e.g. B. 1, 3-di- (2-ethyl-hexyl) -cyclohexane (Cetiol ^® S), as well as volatile and nonvolatile silicone oils, the cyclic, such as. As decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane, or may be linear, for. As linear dimethylpolysiloxane, commercially available z. Example under the name Dow Corning ^® 190, 200, 244, 245, 344 or 345 and Baysilon ^® 350 M. The compositions of the invention may further comprise at least one water-soluble alcohol. Water solubility is understood according to the invention that at least 5 wt .-% of the alcohol at 20 ⁰ C clear dissolve or - in the case of long-chain or polymeric alcohols - by heating the solution to 50 ⁰ C to 60 ⁰ C can be brought into solution. Suitable depending on the dosage form monohydric alcohols such. As ethanol, propanol or isopropanol. Also suitable are water-soluble polyols. These include water-soluble diols, triols and higher alcohols and polyethylene glycols. Among the diols are C ₂ -Ci ₂ - diols, in particular 1, 2-propylene glycol, butylene glycols such as. For example, 1, 2-butylene glycol, 1, 3-butylene glycol and 1, 4-butylene glycol, hexanediols such as. B. 1, 6-hexanediol. Also suitable are preferably glycerol and in particular diglycerol and triglycerol, 1, 2,6-hexanetriol and the dipropylene glycol and the polyethylene glycols (PEG) PEG-400, PEG-600, PEG-1000, PEG-1550, PEG-3000 and PEG-4000 ,

The amount of the alcohol or the alcohol mixture in the compositions according to the invention is 1-98 or 1-70% by weight and preferably 5-40 or 5-55% by weight, based on the total composition. According to the invention, both an alcohol and a mixture of several alcohols can be used.

The compositions of the invention may be substantially anhydrous, d. H. at most 5% by weight, preferably at most 1% by weight, of free water (ie no water of crystallization or hydration). In aqueous dosage forms, the free water content is 5 to 98 wt.%, Preferably 10 to 90 and particularly preferably 15 to 85 wt.%, Based on the total composition.

The compositions of the invention may further comprise at least one hydrophilic modified silicone. They allow the formulation of highly transparent compositions, reduce the stickiness and leave a fresh feeling on the skin. Hydrophilically modified silicones are understood according to the invention to mean polyorganosiloxanes having hydrophilic substituents which cause the water solubility of the silicones. According to the invention is understood to mean water-solubility that solve at least 2 wt .-% of the modified silicone with hydrophilic groups in water at 20 ⁰ C. Corresponding hydrophilic substituents are, for example, hydroxyl, polyethylene glycol or polyethylene glycol / polypropylene glycol side chains and ethoxylated ester side chains. According to the invention are preferably suitable hydrophilic modified silicone copolyols, in particular dimethicone copolyols, for example, by Wacker-Chemie under the name Belsil ^® DMC 6031, Belsil ^® DMC 6032, Belsil ^® DMC 6038 or Belsil ^® DMC 3071 VP or Dow Corning under the name DC 2501 are commercially available. Particularly preferably suitable is the use of Belsil® ^® DMC 6038, as it allows the formulation of highly transparent compositions that achieve higher consumer acceptance. Furthermore, ABIL EM97 from Degussa / Goldschmidt can also be used as the hydrophilic silicone derivative. According to the invention, it is also possible to use any desired mixture of the silicones mentioned.

The amount of the hydrophilic modified silicone or the alcohol mixture in the compositions according to the invention is 0.5-10% by weight, preferably 1-8% by weight and more preferably 2-6% by weight, based on the total weight of the Composition. The compositions of the invention may further contain emulsifiers and / or surfactants. In a particularly preferred embodiment, addition products of 10 to 50 mol of ethylene oxide were linear or branched fatty alcohols having 16 to 22 carbon atoms, fatty acids having 12 to 22 carbon atoms, fatty acid alkanolamides, fatty acid monoglycerides, sorbitan Fatty acid monoesters, of fatty acid alkanolamides, of fatty acid glycerides, for example of hydrogenated castor oil, of methyl glucoside mono-fatty acid esters and mixtures thereof. In principle, however, any other emulsifiers and / or surfactants can be used. The agents according to the invention preferably contain the emulsifiers in amounts of 0.1 to 25% by weight, in particular 0.5 to 15% by weight, based on the total agent. In another, likewise preferred embodiment, at least one ionic emulsifier selected from anionic, zwitterionic, ampholytic and cationic emulsifiers is contained. Preferred anionic emulsifiers are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups, monoglyceride sulfates, alkyl and Alkenyletherphosphate and protein fatty acid condensates. Zwitterionic emulsifiers carry in the molecule at least one quaternary ammonium group and at least one -COO ^" - or -SO ₃ ^" group. Particularly suitable zwitterionic emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, N-acylaminopropyl-N, N-dimethylammonium glycinates and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines in each case 8 to 18 C atoms in the alkyl or acyl group and the Kokosacylaminoethylhydroxyethylcarboxymethylglycinat.

Ampholytic emulsifiers contain, in addition to a C ₈ -C ₂₄ -alkyl or -acyl group, at least one free amino group and at least one -COOH or -SO ₃ H group in the molecule and can form internal salts. Examples of suitable ampholytic emulsifiers are N-alkylglycines, N-

Alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and

Alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group.

The ionic emulsifiers are in an amount of 0.01 to 5 wt .-%, preferably from 0.05 to 3

Wt .-% and particularly preferably from 0.1 to 1 wt .-%, based on the total agent.

Nonionic surfactants which can be used according to the invention are, for example:

- alkoxylated fatty acid alkyl esters of the formula R ¹ CO- (OCH ₂ CHR ² ) _X OR ³ , in which R ¹ CO is a linear or branched, saturated and / or unsaturated acyl radical having 6 to 22 carbon atoms, R ^{2 is} hydrogen or methyl, R ^{3 is} linear or branched alkyl radicals having from 1 to 4 carbon atoms and x is from 1 to 20, addition products of ethylene oxide onto fatty acid alkanolamides and fatty amines, fatty acid N-alkylglucamides, C ₈ -C ₂₂ -alkylamine N-oxides,

Alkyl polyglycosides corresponding to the general formula RO- (Z) _x wherein R is a C ₈ - represents alkyl group, Z is glucose and x is the number of sugar units - Ci. ₆ The alkyl polyglycosides which can be used according to the invention can only contain one particular alkyl radical R. Usually, however, these compounds are prepared starting from natural fats and oils or mineral oils. In this case, the alkyl radicals R are mixtures corresponding to the starting compounds or corresponding to the particular work-up of these compounds. And Ci _O -alkyl groups, essentially of C ₂ - - C ₄ alkyl groups and consists essentially of C ₈ - to C ₆ -alkyl or substantially of Ci ₂ Particularly preferred alkyl polyglycosides in which R consists essentially of C ₈ - to Ci ₆ - alkyl groups. As sugar building block Z it is possible to use any desired mono- or oligosaccharides.

Suitable zwitterionic surfactants are surface-active compounds which carry at least one quaternary ammonium group and at least one -COO ⁽⁾ or -SO ₃ ⁽⁾ group in the molecule. Particularly suitable zwitterionic surfactants are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl-3 - Hydroxyethylimidazoline having in each case 8 to 18 carbon atoms in the alkyl or acyl group and Kokosacylaminoethylhydroxyethylcarboxymethylglycinat. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine. Suitable anionic surfactants in compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. Example, a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group with about 8 to 30 C Atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule.

Furthermore, the compositions according to the invention may contain at least one protein hydrolyzate or its derivative. Both vegetable and animal protein hydrolysates can be used according to the invention. Animal protein hydrolysates are z. B. elastin, collagen, keratin, silk and milk protein protein hydrolysates, which may also be in the form of salts. Vegetable protein hydrolysates, eg. Soy, wheat, almonds, peas, potato and rice protein hydrolysates. Instead of the protein hydrolysates, amino acid mixtures obtained on the one hand and, on the other hand, individual amino acids and their physiologically tolerated salts can also be used. The inventively preferred amino acids include glycine, serine, threonine, cysteine, asparagine, glutamine, pyroglutamic acid, alanine, VaNn, leucine, isoleucine, proline, tryptophan, phenylalanine, methionine, aspartic acid, glutamic acid, lysine, arginine and histidine, and the zinc salts and Acid addition salts of said amino acids. Also possible is the use of derivatives of protein hydrolysates, z. In the form of their fatty acid condensation products.

Cationized protein hydrolysates can also be used according to the invention, it being possible for the underlying protein hydrolyzate to originate from the animal, from the plant, from marine life forms or from biotechnologically obtained protein hydrolysates. Preference is given to cationic protein hydrolysates whose protein content on which they are based has a molecular weight of from 100 to 25,000 daltons, preferably from 250 to 5,000 daltons. Furthermore, cationic protein hydrolyzates are to be understood as meaning quaternized amino acids and mixtures thereof. Furthermore, the cationic protein hydrolysates may also be further derivatized. Very particular preference is given to the cationic protein hydrolysates and derivatives based on plants. In the compositions according to the invention are the protein hydrolysates and their derivatives or the amino acids and their derivatives in amounts of up to 10 wt .-%, based on the total agent included. Amounts of 0.1 to 5 wt .-%, in particular 0.1 to 3 wt .-%, are particularly preferred.

Furthermore, the compositions according to the invention may contain at least one mono-, oligo- or polysaccharide or derivatives thereof.

According to the invention suitable monosaccharides are z. As glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose and talose, the deoxy sugars fucose and rhamnose and amino sugars such. As glucosamine or galactosamine. According to the invention suitable oligosaccharides are composed of two to ten monosaccharide units, for. As sucrose, lactose or trehalose. A particularly preferred oligosaccharide is sucrose. Also particularly preferred is the use of honey, which contains predominantly glucose and sucrose.

Polysaccharides which are suitable according to the invention are composed of more than ten monosaccharide units. Preferred polysaccharides are the starches made from α-D-glucose units and starch degradation products such as amylose, amylopectin and dextrins. According to the invention particularly advantageous are chemically and / or thermally modified starches, for. Hydroxypropyl starch phosphate, dihydroxypropyldistarch phosphate or the commercial products Dry ^Flo® . Further preferred are dextrans and their derivatives, eg. B. dextran sulfate. Also preferred are nonionic cellulose derivatives such as methylcellulose, hydroxypropylcellulose or hydroxyethylcellulose, as well as cationic cellulose derivatives, e.g. , The commercial products Celquat ^® and Polymer JR ^®, and preferably Celquat ^® H 100, Celquat L 200 and Polymer JR ^{® ®} 400 (Polyquaternium-10) as well as Polyquaternium-24th Further preferred examples are polysaccharides from fucose units, e.g. B. the commercial product Fucogel ^® . Particularly preferred are the polysaccharides composed of amino sugar units, in particular chitins and their deacetylated derivatives, the chitosans, and mucopolysaccharides. The inventively preferred mucopolysaccharides include hyaluronic acid and its derivatives, e.g. As sodium hyaluronate or Dimethylsilanolhyaluronat, and chondroitin and its derivatives, for. B. chondroitin sulfate. In an advantageous embodiment, the compositions according to the invention comprise at least one film-forming, emulsion-stabilizing, thickening or adhesive polymer selected from natural and synthetic polymers which may be cationic, anionic, amphoteric or nonionic.

Cationic, anionic and nonionic polymers are preferred according to the invention. Preferred among the cationic polymers are polysiloxanes with quaternary groups. Preferred anionic polymers which can support the action of the active ingredient used according to the invention comprise carboxylate and / or sulfonate groups and as monomers, for example, acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. The acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid. Very particularly preferred anionic polymers contain 2-acrylamido-2-methylpropanesulfonic acid as the sole monomer or as comonomer, it being possible for the sulfonic acid group to be wholly or partly in salt form. Within this embodiment, it is preferred to use copolymers of at least one anionic monomer and at least one nonionic monomer. With regard to the anionic monomers, reference is made to the substances listed above. Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters. Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. A particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid groups wholly or partly as sodium, potassium, ammonium, mono- or Triethanolammonium salt present. This copolymer can also be crosslinked, with preference being given to polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide as crosslinking agents. Such a polymer is contained in the commercial product Sepigel ^® 305 from SEPPIC. The usage This compound has proven to be particularly advantageous in the context of the teaching of the invention. Also sold under the name Simulgel ^® 600 as a compound with isohexadecane and polysorbate-80 Natriumacryloyldimethyltaurat copolymers have proved to be particularly effective according to the invention.

Further preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example the commercial products Carbopol ^®. A particularly preferred anionic copolymer contains as monomer 80-98% of an unsaturated, optionally substituted C ₃ . _6- carboxylic acid or its anhydride and to 2 - 20%, if desired, substituted acrylic acid esters of saturated C ₁₀ - ₃ o-carboxylic acids, wherein the copolymer can be crosslinked with the aforementioned crosslinking agents. Corresponding commercial products are Pemulen ^® and Carbopol ^® grades 954, 980, 1342 and ETD 2020 (ex BF Goodrich).

Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for. B. the commercial products Mowiol ^® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidones z. B. under the trademark Luviskol ^® (BASF) are sold. The compositions of the invention may further contain at least one α-hydroxycarboxylic acid or α-ketocarboxylic acid or their ester, lactone or salt form. Suitable α-hydroxycarboxylic acids or α-ketocarboxylic acids are selected from lactic acid, tartaric acid, citric acid, 2-hydroxybutanoic acid, 2,3-dihydroxypropanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxydecanoic acid, 2-hydroxydodecanoic acid , 2-hydroxytetradecanoic acid, 2-

Hydroxyhexadecanoic, 2-hydroxyoctadecanoic, mandelic, 4-hydroxymandelic, malic, erythraric, threaric, glucaric, galactaric, mannaric, gularic, 2-hydroxy-2-methylsuccinic, gluconic, pyruvic, glucuronic and galacturonic acid. The esters of said acids are selected from the methyl, ethyl, propyl, isopropyl, butyl, amyl, pentyl, hexyl, 2-ethylhexyl, octyl, decyl, dodecyl and hexadecyl esters. The α-hydroxycarboxylic acids or α-ketocarboxylic acids or their derivatives are present in amounts of from 0.1 to 10% by weight, preferably 0.5 to 5% by weight, in each case based on the total composition.

The agents according to the invention may contain further active ingredients, auxiliaries and additives, for example vitamins, provitamins and vitamin precursors from groups A, C and E, in particular 3,4-didehydroretinol (vitamin A ₂ ), .beta.-carotene (provitamin of vitamin A ₁ Ascorbic acid (vitamin C), as well as the palmitic acid esters, glucosides or phosphates of ascorbic acid, tocopherols, in particular α-tocopherol and its esters, for. The acetate, the nicotinate, the phosphate and the succinate;

Vitamins, provitamins or vitamin precursors of the vitamin B group or derivatives thereof and derivatives of 2-furanone, in particular vitamin B ₁ (thiamine), vitamin B ₂ (riboflavin), vitamin B ₃ (Nicotinic acid and / or nicotinic acid amide), vitamin B ₅ (pantothenic acid and / or panthenol), vitamin B ₆ (pyridoxine, pyridoxamine and / or pyridoxal) and / or vitamin B ₇ (biotin), allantoin,

Ceramides and pseudoceramides,

Triterpenes, in particular triterpenic acids such as ursolic acid, rosmarinic acid, betulinic acid, boswellic acid and bryonic acid,

Monomeric catechins, especially catechin and epicatechin, leucoanthocyanidins, catechin polymers (catechin tannins) and gallotannins,

Thickener, z. As gelatin, plant matter such as agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum or locust bean gum, natural and synthetic clays and phyllosilicates, z. As bentonite, hectorite, montmorillonite or Laponite ^® , fully synthetic hydrocolloids such. As polyvinyl alcohol, and also Ca, Mg or Zn soaps of fatty acids, vegetable glycosides,

Structurants such as maleic acid and lactic acid, dimethyl isosorbide,

Alpha, beta and gamma cyclodextrins, in particular for the stabilization of retinol, solvents, swelling and penetrating substances such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerol and diethylene glycol, carbonates, bicarbonates, guanidines, ureas and primary, secondary and tertiary Phosphate

Perfume oils, pigments and dyes for coloring the agent, substances for adjusting the pH, z. B. α- and ß-hydroxycarboxylic acids, complexing agents such as EDTA, NTA, ß-Alanindiessigsäure and phosphonic acids, opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers, propellants such as propane-butane mixtures, N ₂ O, dimethyl ether, CO ₂ and air, MMP-1 inhibiting substances, in particular selected from photolyase and / or T4 endonuclease V, propyl gallate, precocenes, 6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) -benzopyran and 3, 4-Dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) -benzopyran, organic, mineral and / or modified mineral sunscreen filters, in particular UVA filters and / or UVB filters.

Deodorant or antiperspirant sticks according to the invention may be in gelled form, on anhydrous wax base and based on W / O emulsions and O / W emulsions. Gel sticks can be prepared on the basis of fatty acid soaps, dibenzylidene sorbitol, N-acyl amino acid amides, 12-hydroxystearic acid and other gel formers. Aerosol sprays, pump sprays, roll on applications and creams can be used as water-in-oil emulsion, oil-in-water emulsion, silicone oil-in-water emulsion, water-in-oil microemulsion, oil-in-water Microemulsion, silicone oil-in-water microemulsion, anhydrous suspension, alcoholic and hydroalcoholic solution, aqueous gel and as an oil. All said compositions may be thickened, for example, on the basis of fatty acid soaps, dibenzylidenesorbitol, N-acylamino acid amides, 12-hydroxystearic acid, carbomer and carbopol type polyacrylates, polyacrylamides and polysaccharides, which may be chemically and / or physically modified, and on a base basis of fatty alcohols in combination with hardened triglycerides, especially in combination with hydrogenated castor oil (Cutina® HR). The emulsions and microemulsions may be transparent, translucent or opaque.

Liquid and gelatin dosage forms of the compositions of the invention may contain thickening agents, e.g. As cellulose ethers, such as hydroxypropyl cellulose, hydroxyethyl cellulose and methyl hydroxypropyl cellulose, thickening polymers based on polyacrylates, which may be crosslinked, if desired, for. As the Carbopol types or Pemulen ^® - products, or based on polyacrylamides or sulfonic acid containing polyacrylates, eg. B Sepigel ^® 305 or Simulgel® ^® EG, also inorganic thickeners such. B. Bentonite and Hectorite (Laponite ^®).

The compositions of the invention may contain other cosmetically and dermatologically active substances, such as anti-inflammatory substances, solids selected from silicic acids, eg. As Aerosil ^® types, silica gels, silica, clays, z. B. bentonite or kaolin, magnesium aluminum silicates, z. Talc, boron nitride, titanium dioxide, which may if desired be coated, optionally modified starches and starch derivatives, cellulose powders and polymer powders, furthermore plant extracts, protein hydrolysates, vitamins, perfume oils, sebostatics, anti-acne agents and keratolytics. The compositions according to the invention, insofar as they are liquid, can be applied to flexible and absorbent carriers and offered as deodorant or antiperspirant wipes or sponges. As a flexible and absorbent carrier in the context of the invention, z. As carriers of textile fibers, collagen or polymeric foams. As textile fibers, both natural fibers such as cellulose (cotton, linen), silk, wool, regenerated cellulose (viscose, rayon), cellulose derivatives and synthetic fibers such as polyester, polyacrylonitrile, polyamide or polyolefin fibers or mixtures of such fibers can be woven or unwoven. These fibers may be made into absorbent cotton pads, nonwovens or woven or knitted fabrics. Also flexible and absorbent polymeric foams, eg. As polyurethane foams and polyamide foams are suitable substrates. The substrate may have one, two, three and more than three layers, wherein the individual layers may consist of the same or different materials. Each substrate layer may have a homogeneous or an inhomogeneous structure with, for example, different zones of different densities.

According to the invention, the dosage form is furthermore preferred as an aerosol, the cosmetic composition being a propellant, preferably selected from propane, butane, isobutane, pentane, isopentane, dimethyl ether, fluorohydrocarbons and chlorofluorocarbons contains. Likewise, a compressed propellant such as air, nitrogen or carbon dioxide can be used. Likewise, mixtures of the stated blowing agents can be used. In a preferred embodiment, the compositions according to the invention are in the form of a liquid or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, microemulsion, PIT emulsion or Pickering emulsion, a hydrogel, a lipogel, a single- or multi-phase solution, a foam, a powder or a mixture with at least one polymer suitable as a medical adhesive. The agents may also be presented in anhydrous form, such as an oil or a balm. Here, the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.

In a particular embodiment of the agents according to the invention, the agents are present as microemulsions. In the context of the invention, microemulsions are understood to mean not only the thermodynamically stable microemulsions but also the so-called "PIT" emulsions. These emulsions are systems with the 3 components water, oil and emulsifier, which are present at room temperature as an oil-in-water emulsion. When these systems are heated, microemulsions form in a certain temperature range (referred to as the phase inversion temperature or "PIT") and, upon further heating, convert to water-in-oil (W / O) emulsions. Upon subsequent cooling, O / W emulsions are again formed, but they are also present at room temperature as microemulsions or as very finely divided emulsions having an average particle diameter of less than 400 nm and in particular of about 100-300 nm. According to the invention, those micro- or "PIT" emulsions may be preferred which have an average particle diameter of about 200 nm. Details regarding these "PIT emulsions" z. From Angew. Chem. 97, 655 - 669 (1985). Another preferred subject matter of the present invention are compositions for oral care, which are to be understood as oral, dental and / or dental prosthesis care agents containing urea derivatives according to the invention and / or phenacylthiazolium salts. The oral, dental and / or dental prosthesis care agents according to the invention can be present, for example, as a mouthwash, gel, liquid toothbrush lotion, stiff toothpaste, chewing gum, denture cleaner or denture adhesive cream.

For this purpose, it is necessary to incorporate the urea derivatives and / or phenacylthiazolium salts in a suitable carrier.

As a carrier, for example, pulverulent preparations or aqueous-alcoholic solutions can be used, as mouthwash 0 to 15 wt .-% ethanol, 1 to 1, 5 wt .-% flavor oils and 0.01 to 0.5 wt .-% sweeteners or as mouthwash concentrates 15 to 60 wt .-% ethanol, 0.05 to 5 wt .-% flavor oils, 0.1 to 3 wt .-% sweeteners and optionally other excipients may be included and diluted with water before use. The concentration of the components must be so high that, after dilution, the specified lower concentration limits are not undershot during use. However, gels and more or less flowable pastes, which are expressed from flexible plastic containers or tubes and applied to the teeth with the aid of a toothbrush, can also serve as the carrier. Such products contain higher levels of humectants and binders or consistency regulators and polishing components. In addition, aromatic oils, sweeteners and water are also contained in these preparations.

As humectants, e.g. Glycerol, sorbitol, xylitol, propylene glycols, Polyethenylenglycole or mixtures of these polyols, in particular those Polyethenylenglycole be used with molecular weights of 200 to 800 (from 400 to 2000). Preferably, sorbitol is contained as humectant in an amount of 25-40 wt .-%. As anticalculus agents and as demineralization inhibitors, condensed phosphates may be present in the form of their alkali metal salts, preferably in the form of their sodium or potassium salts. The aqueous solutions of these phosphates react alkaline due to hydrolytic effects. By addition of acid, the pH of the oral, dental and / or dental prosthesis care agents according to the invention is adjusted to the preferred values of 7.5-9.

It is also possible to use mixtures of different condensed phosphates or else hydrated salts of the condensed phosphates. The specified amounts of 2-12% by weight, however, refer to the anhydrous salts. Preferably, the condensed phosphate is a sodium or potassium tripolyphosphate in an amount of 5-10% by weight of the composition.

A preferred active ingredient is a caries-inhibiting fluorine compound, preferably from the group of fluorides or monofluorophosphates in an amount of 0.1 to 0.5 wt .-% fluorine. Suitable fluorine compounds are, for example, sodium monofluorophosphate (Na ₂ PO ₃ F), potassium monofluorophosphate, sodium or potassium fluoride, tin fluoride or the fluoride of an organic amino compound.

Suitable binders and consistency regulators are, for example, natural and synthetic water-soluble polymers such as carrageenan, tragacanth, guar, starch and their non-ionic derivatives such as hydroxypropyl guar, hydroxyethyl starch, cellulose ethers such as hydroxyethyl cellulose or methylhydroxypropyl cellulose. Also, agar-agar, xanthan gum, pectins, water-soluble carboxyvinyl polymers (for example Carbopol ^® types), polyvinyl alcohol, polyvinyl pyrrolidone, high molecular weight polyethylene glycols (molecular weight 10 ³ to 10 ⁶ D). Further substances which are suitable for viscosity control are phyllosilicates such as montmorillonite clays, colloidal thickening silicas, eg airgel silica or fumed silicas. As polishing components may all heretofore known polishing agent, but preferably precipitated and gel silicas, aluminum hydroxide, aluminum silicate, alumina, alumina trihydrate, insoluble sodium metaphosphate, calcium pyrophosphate, calcium hydrogen phosphate, dicalcium phosphate, chalk, hydroxyapatite, hydrotalcites, talc, magnesium aluminum silicate (Veegum ^®), calcium sulfate, magnesium carbonate, Magnesium oxide, sodium aluminum silicates, eg Zeolite A or organic polymers, such as polymethacrylate, are used. The polishing agents are preferably used in smaller amounts of eg 1-10% by weight. The dental and / or oral care products according to the invention can be improved in their organoleptic properties by adding aroma oils and sweeteners. Aromatic oils are all natural and synthetic flavors which are customary for oral, dental and / or dental care products. Natural flavors can be used both in the form of the essential oils isolated from the drugs and the individual components isolated from them. Preferably, at least one aromatic oil from the group of peppermint oil, spearmint oil, aniseed oil, caraway oil, eucalyptus oil, fennel oil, cinnamon oil, geranium oil, sage oil, thyme oil, marjoram oil, basil oil, citrus oil, Gaultheria oil or one or more synthetic components of these oils isolated therefrom should be included. The most important components of the oils mentioned are, for example, menthol, carvone, anethole, cineole, eugenol, cinnamaldehyde, geraniol, citronellol, linalool, salvos, thymol, terpinene, terpinol, methylchavicol and methyl salicylate. Further suitable flavors are, for example, menthyl acetate, vanillin, ionone, linalyl acetate, rhodinol and piperitone. Suitable sweeteners are either natural sugars such as sucrose, maltose, lactose and fructose or synthetic sweeteners such as saccharin sodium salt, sodium cyclamate or aspartame.

In particular, alkyl and / or alkenyl (oligo) glycosides can be used as surfactants. Their preparation and use as surface-active substances are described, for example, in US Pat. No. 3,839,318, US Pat. No. 3,707,535, US Pat. No. 3,547,828, DE-A-19 43 689, DE-A-20 36 472 and US Pat DE-A-30 01 064 and EP-A-77 167 known. With regard to the glycoside radical, monoglycosides (x = 1) in which a pentose or hexose radical is glycosidically bonded to a primary alcohol having 4 to 16 carbon atoms, as well as oligomeric glycosides having a degree of oligomerization x to 10, are suitable. The degree of oligomerization is a statistical mean, which is based on a homolog distribution typical for such technical products.

As alkyl and / or alkenyl (oligo) glycoside, an alkyl and / or alkenyl (oligo) glucoside of the formula RO (C ₆ H ₁₀ O) _x -H in which R is an alkyl radical and is preferably suitable / or alkenyl group having 8 to 14 carbon atoms and x has an average of 1 to 4. Particularly preferred are alkyl oligoglucoside glucoside based on hydrogenated _{C12 /} i ₄ coconut alcohol with a DP of 1 to 3. The alkyl and / or alkenyl glycoside surfactant can be used very sparingly, wherein already weight amounts of 0.005 to 1 .-% are sufficient.

In addition to the alkyl glucoside surfactants mentioned, other nonionic, ampholytic and cationic surfactants may also be present, for example: fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, monoglyceride ether sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides, fatty acid glutamates,

Ethercarbonsäuren, Fettsäureglucamide, Alkylamido betaine and / or protein fatty acid condensates, the latter preferably based on wheat proteins. In particular, to solubilize the usually water-insoluble aroma oils, a non-ionic solubilizer from the group of surface-active compounds may be required. Particularly suitable for this purpose, for example ethoxylated fatty acid glycerides, ethoxylated fatty acid sorbitan partial esters or fatty acid partial esters of glycerol or sorbitan ethoxylates. Solubilizers from the group of ethoxylated Fettsäureglyceride include especially addition products of 20 to 60 moles of ethylene oxide with mono- and diglycerides of linear fatty acids having 12 to 18 carbon atoms or triglycerides of hydroxy fatty acids such as oxystearic acid or ricinoleic acid. Further suitable solubilizers are ethoxylated fatty acid sorbitan partial esters; these are preferably addition products of 20 to 60 moles of ethylene oxide with sorbitan monoesters and sorbitan diesters of fatty acids with 12 to 18 carbon atoms. Also suitable solubilizers are fatty acid partial esters of glycerol or sorbitan ethoxylates; these are preferably mono- and diesters of C ₁₂ -C ₁₈ -fatty acids and adducts of 20 to 60 moles of ethylene oxide with 1 mole of glycerol or 1 mole of sorbitol.

The oral, dental and / or dental prosthesis care agents according to the invention preferably contain as solubilizer for optionally contained aroma oils addition products of 20 to 60 moles of ethylene oxide to hardened or uncured castor oil (ie to Oxystearinsäure- or ricinoleic acid triglyceride), to glycerol mono- and / or distearate or sorbitan mono- and / or distearate. Other common additives for oral, dental and / or denture care medium are e.g.

Pigments, e.g. Titanium dioxide, and / or dyes, pH adjusters and buffering agents, e.g. Sodium bicarbonate, sodium citrate,

Sodium benzoate, citric acid, phosphoric acid or acid salts, eg NaH ₂ PO ₄ wound-healing and anti-inflammatory substances such as allantoin, urea, panthenol,

Azulene or chamomile extract further anti-calculus substances such. Organophosphonates, e.g.

Hydroxyethane diphosphonates or azacycloheptane diphosphonate

Preservatives such as e.g. Sorbic acid salts, p-hydroxybenzoic acid esters.

Plaque inhibitors, e.g. Hexachlorophene, chlorhexidine, hexetidine, triclosan,

Bromochlorophene, phenylsalicylic acid ester.

In a particular embodiment, the composition is a mouthwash, a mouthwash, a denture cleanser or a denture adhesive.

For prosthesis cleaners according to the invention, in particular prosthesis cleansing tablets and powders, in addition to the already mentioned ingredients for oral, dental and / or dental prosthesis care, per-compounds such as, for example, peroxoborate, peroxomonosulfate or percarbonate are additionally suitable. They have the advantage that, in addition to the bleaching effect, they simultaneously have a deodorizing and / or disinfecting effect. The use of such per-compounds in prosthesis cleaners is between 0.01 and 10 wt .-%, in particular between 0.5 and 5 wt .-%.

Other ingredients include enzymes such as proteases and carbohydrase, for the degradation of proteins and carbohydrates. The pH can be between pH 4 and pH 12, in particular between pH 5 and pH 11. For the prosthesis cleansing tablets in addition, other auxiliaries are necessary, such as agents that cause a bubbling effect, such as CO ₂ releasing substances such as sodium bicarbonate, fillers, such as sodium sulfate or dextrose, lubricants, eg

Magnesium stearate, flow control agents such as colloidal silica and

Granulating agents, such as the already mentioned high molecular weight polyethylene glycols or

Polyvinylpyrrolidone.

Denture adhesives can be offered as powders, creams, foils or liquids and support the adhesion of the prostheses.

As active ingredients natural and synthetic swelling substances are suitable. As natural swelling agents, besides alginates, plant gums, such as e.g. Gum arabic, tragacanth and karaya gum as well as natural rubber. In particular, alginates and synthetic have

Swelling agents, e.g. Sodium carboxymethylcellulose, high molecular weight ethylene oxide copolymers,

Salts of poly (vinyl ether-co-maleic acid) and polyacrylamides.

As adjuvants for pasty and liquid products are particularly hydrophobic bases, in particular hydrocarbons, such as white Vaseline (DAB) or paraffin oil.

embodiments

The following examples are intended to illustrate the invention without being limited thereto.

Example 1: Assay for detection of cystathionine beta-lyase activity

Substances were assayed for their inhibitory activity against cystathionine beta-lyase (CBL, E.C. 4.4.1.8) by a fluorescence-based assay of a crude extract from a Stapylococcus sp. (Self-isolate Henkel AG and Co. KGaA) tested out. The cysteine released from the substrate during the assay forms a fluorescent complex with monobromobimane.

1.1 Preparation of a crude extract from Staphylococcus sp .:

• Cultivation of Staphylococcus sp. on CaSo agar at 37 ° C for about 48 h

• Wash the cells with Sörensen buffer pH 7.0 (~ 10 ml / 6 plates)

• Pelleting by centrifugation, washing 3 times with Sörensenpuffer

Mechanical disruption of the cells in Sörensen buffer (1 ml / g cells) by means of ball mill (Retsch) or FastPrep Cell Disruptor (MP Biomedicals)

• centrifugation of cell debris

Determination of the protein content of the crude extract with a commercial kit, e.g. Uptima BC assay

• Store at -20 ⁰ C.

1.2 Photometric test for CBL activity and evaluation

• Assay:

0.25 mM benzylcysteine

0.1 mM monobromobimane

50 μl of crude extract from Staphylococcus sp.

Add 2.5 μl of inhibitor (for 1% AWK) to 250 μl with Sörensen buffer pH 7.5

Measurement of CBL activity as fluorescence increase at 460 nm for 30 min. in a fluorimeter (excitation with blue light of 390 nm)

Calculation of specific CBL activity as Δ fluorescence / min x mg protein. All measured values are previously corrected for blank values (raw extract replaced by buffer)

Comparison of specific CBL activities with and without inhibitor (control)

1.3. Results

Specific CBL activities of a Sfapy / ococcous crude extract under the influence of various

Inhibitors relative to control (mean ± SEM, n = 2 - 3 independent replicates).

AWK: application concentration; SEM: standard error of the mean value

Example 2: Synthesis Examples

2.1. Preparation of a sulfonylurea

2.1.1. Reaction of tosylsulfonic acid isocyanate with methyl anthranilate

Methyl anthranilate p-tosylsulfonic acid isocyanate

In a 250 ml three-necked flask, 4.38 g (28.7 mmol) of methyl anthranilate were dissolved in 20 ml of dichloromethane under a nitrogen atmosphere. 5.96 g (28.7 mmol) of p-tosylsulfonic acid isocyanate were dissolved in 20 ml of dichloromethane and slowly added dropwise at 0 ⁰ C within one hour. It was stirred overnight. Subsequently, the solvent was removed in vacuo. A clear, colorless, highly viscous oil was obtained. Using the heating bath, the removal of solvent residues was carried out until the onset of crystallization. Subsequently, further crystallization took place in the refrigerator and then drying in vacuo. The yield was 9.7 g (27.8 mmol, 97%).

TLC (toluene / ethyl acetate 3: 1): R _f = 0.17-0.23

¹ H-NMR (400 MHz, CDCl ₃ , TMS): δ = 8.30 (d, 1H, H-2), 8.03 (d, 1H, H-5), 7.95 (d, 2H, H-8) , 7.50 (t, 1H, H-4), 7.30 (d, 2H, H-9), 7.10 (t, 1H, H-3), 4.00 (s, 3H, H-1), 2.42 (s , 3H, H-10). 2.1.2. saponification

In a 100 ml three-necked flask, 2.5 g (7.2 mmol) of the starting material was dissolved in 62 ml of methanol. It was adjusted to pH = 9 with 2 M sodium hydroxide solution and heated to reflux for 2 hours. After TLC monitoring (toluene / ethyl acetate 3: 1) was heated to reflux for a further 4 hours. Since the reaction was still incomplete, a few granules of solid sodium hydroxide were added and heated to reflux for 6 hours. It was neutralized with acetic acid (conc.) And adjusted to pH = 5. The solvent was removed in vacuo to give a yellow oil. Dissolution in toluene, ethyl acetate and dichloromethane for purification through a filter column was unsuccessful. After adding water, a cloudy mixture was obtained. After addition of ethyl acetate, crystallization of a colorless solid was carried out, which was filtered off with suction. The yield was 1.1 g (3.3 mmol, 46%).

TLC (toluene / ethyl acetate 3: 1): R _f = 0

¹ H-NMR (400 MHz, DMSO, DMSO): δ = 10.35 (br, S, 1H, COOH), 8.39 (d, 1H, Ar-H), 7.86 (d, 1H, Ar-H) , 7.70 (d, 2H, Ar-H), 7.36 (t, 1H, Ar-H), 7.22 (d, 2H, Ar-H), 6.83 (t, 1H, Ar-H), 2.33 (s , 3H, Ar-CH ₃ ).

2.2. Synthesis of phenacylthiazolium chloride

Formula Weight = 85 12762 Cl -

Formula Weight = 239 7206514

Formula Weight = 154 59358

15.46 g (0.10 mol) of 2-chloroacetophenone were weighed out and dissolved in 60 ml of ethyl acetate. The clear solution was heated to 75 ° C and added dropwise with stirring 4.4 ml (0.0624 mmol) of thiazole. The resulting clear solution was then stirred for 3.5 hours at reflux and then allowed to stand for one day under a nitrogen atmosphere and the resulting suspension is filtered off with suction and dried under high vacuum. The yield was 1.94 g (13%).

Example 3: Formulation Examples

Antiperspirant sticks according to the invention based on an oil-in-water emulsion (amounts in% by weight)

Formulation Example 8: Antiperspirant Emulsion (O / W) According to the Invention

The emulsion according to Formulation Example 8 had the first day after the preparation has a viscosity of 2200 mPas, measured with a Brookfield viscometer, spindle RV 4, 20 s-1 without Helipath, at 20 ⁰ C ambient temperature and 20 ⁰ C sample temperature; she was filled into a roll-on applicator.

Formulation Example 9: Antiperspirant Emulsion (O / W) According to the Invention

The emulsion according to Formulation Example 9 had the first day after the preparation has a viscosity of 1700 mPas, measured with a Brookfield viscometer, spindle RV 4, 20 s-1 without Helipath, at 20 ⁰ C ambient temperature and 20 ⁰ C sample temperature; she was filled into a roll-on applicator.

Soap-containing pens (in% by weight)

Anhydrous deodorant spray (in% by weight)

Suspension type antiperspirant spray (in% by weight)

Antiperspirant wipes (Formulation Examples No. 17.1 - 17.4)

For the embodiment according to the invention as an antiperspirant cloth, a single-layer substrate of 100% viscose with a weight per unit area of 50 g / m ^{2 was used} , each with 75 g of the example emulsions

1 1.1 or 11.2 or 2.3 per square meter or with 75 g each of the sample solutions 13.1 or

13.2, cut into cloths of suitable size and packed in sachets.

Water-in-oil emulsion spray

W / O-Eimulsions Compact Spray

Example Composition 19.1 contains an antiperspirant emulsion according to the invention with 9.9% by weight aluminum chlorohydrate, based on the weight of the propellant-free emulsion. With a spray rate of 0.35 g / s, 0.035 g of the antiperspirant active ingredient aluminum chlorohydrate are sprayed onto the skin surface every second.

Example Composition 19.2 contains an antiperspirant emulsion according to the invention with 17.49% by weight aluminum chlorohydrate, based on the weight of the propellant-free emulsion. At a spray rate of 0.2 g / s, 0.035 g of the antiperspirant active ingredient aluminum chlorohydrate is sprayed onto the skin surface every second. Liquid tooth cleaning gels

List of raw materials used

Component INCI Supplier / Manufacturer

Aethoxal ^® B PPG-5 laureth-5 Cognis

Alutrat ^® aluminum citrate Vevy

Cekol 2000 Sodium Carboxymethylcellulose Metsa

Cetiof OE DICAPRYLYL ETHER Cognis

Cremophor ^® RH 455 hydrogenated castor oil with 40 EO, BASF propylene glycol-containing

Cutina ^® AGS Glycol Distearate Cognis

Cutina ^® EGMS Glycol Stearate Cognis

Claims

claims

1. Use of urea derivatives and / or phenacylthiazolium salts for the prevention or treatment of body odor, especially in the axillary or oral area.

2. Use of compounds selected from urea derivatives and phenacylthiazolium salts or mixtures thereof for inhibiting cystathionine beta-lyase.

3. Use according to claim 1 or 2, characterized in that the urea derivative is selected from sulfonylureas, acylureas, sulfonylthioureas and acylthioureas.

4. Use according to claim 3, characterized in that the sulfonylureas, acylureas, sulfonylthioureas and acylthioureas are selected from compounds of the general formulas R ¹ -SO ₂ -NX-C (O) -NY-R ² , R ¹ -C (O ) -NX-C (O) -NY-R ² , R ¹ -SO ₂ -NX-C (S) -NY-R ² and R ¹ -C (O) -NX-C (S) -NY-R ² , each being characterized in that X, Y, R ¹ and R ^{2 are} independently trifluoromethyl, hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, alkoxy, alkoxyalkyl, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkanoyl, alkanoyloxy , Alkoxycarbonyl, alkylaminocarbonyl, alkylsulfanylcarbonyl, hydroxy, hydroxyalkyl, hydroxycarbonyl, amino, alkylamino, aryl, arylalkyl, aryloxy, arylamino, arylsulfanyl, arylsulfinyl, arylsulfonyl, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyl, arylaminocarbonyl, arylsulfanylcarbonyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylamino, heteroarylsulfanyl , Heteroarylsulfonyl, heteroaryl lsulfoxidyl, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroaryloxycarbonyl, heteroarylaminocarbonyl, heteroarylsulfanylcarbonyl, alkoxysulfonyl, alkoxycarbinol, sulfo, sulfino, sulfeno, formyl or thioformyl, all radicals of the resulting molecule may each independently or optionally also be mono- or polysubstituted.

5. Use according to claim 4, characterized in that it is in the urea derivative to a sulfonylurea according to formula (I) or (II)

or a sulfonylthiourea according to formula (IM) or (IV)

or mixtures thereof, each with R = hydrogen or C- | _6- alkyl and wherein said compounds may optionally also carry further substituents.

6. Use according to one of claims 1 to 5, characterized in that the phenacylthiazolium salt is an optionally substituted cation according to formula (V)

includes.

Use according to claim 6, characterized in that the phenacylthiazolium salt is phenacylthiazolium chloride.

8. Use according to one of claims 1 to 7, characterized in that the use takes place in a cosmetic or pharmaceutical agent.

9. Use according to claim 8, characterized in that the cosmetic or pharmaceutical agent is a deodorant or antiperspirant.

10. A cosmetic or pharmaceutical composition for the treatment or prevention of body odor or halitosis containing urea derivatives and / or phenacylthiazolium salts.

11. Cosmetic or pharmaceutical composition according to claim 10, characterized in that it is a deodorant or antiperspirant.

12. Cosmetic or pharmaceutical composition according to claim 1 1, characterized in that the deodorant or antiperspirant at least one proline in the axillary area effective substance selected from plants extra kten from Picea spp., Pinus sp., Paullinia sp., Panax sp., Lamium sp., Ribes sp., Camellia spec., Hibiscus spec., Malva spec., Vitis sp., Daucus sp., Commiphora sp., Simmondsia spec. or Calendula spec, Glycerinmonoalkylether, in particular 1- (2-ethylhexyl) glycerol ether, isopropyl myristate or ethyl myristate or mixtures thereof.

13. Cosmetic or pharmaceutical composition according to claim 11 or 12, characterized in that the deodorant or antiperspirant at least one further deodorant active ingredient selected from fragrances, odor absorbers, deodorizing ion exchangers, antimicrobial or antimicrobial agents, other enzyme-inhibiting substances, antioxidants, odor adsorbents and an aromatic alcohol of the general formula

wherein R ¹ - R ⁶ = independently represent a hydrogen atom, a linear or branched and optionally substituted C- _M o-alkyl group or a linear or branched and optionally substituted C ₂ -io-alkenyl group, wherein the substituents are each preferably selected are selected from hydroxy and CI_ ₆ alkoxy,

R ⁷ - R ¹¹ = independently a hydrogen atom, a halogen atom, especially chlorine, or a linear or branched and optionally substituted Ci- io alkyl group, wherein the substituents are preferably selected from hydroxy and Ci _-6 -

Alkoxy, in particular methoxy, m = 0 or 1, n, o, p = can independently be integers from 0 to 10, wherein at least one of the values of n, o, p ≠ 0.

14. Cosmetic or pharmaceutical composition according to claim 10, characterized in that it is a means for oral care.

15. Use of urea derivatives and / or phenacylthiazolium salts for the preparation of a cosmetic or pharmaceutical composition for the treatment or prevention of body odor, in particular in the axillary or oral area.